Literature DB >> 11406322

Idebenone in patients with Friedreich ataxia.

L Schöls1, M Vorgerd, M Schillings, G Skipka, J Zange.   

Abstract

Friedreich ataxia (FA), the most common form of degenerative ataxia, is thought to be caused by respiratory deficiency due to mitochondrial iron accumulation and oxidative stress. Idebenone, a free-radical scavenger, protects mitochondrial function in in vitro models of FA. In a placebo-controlled crossover trial we studied the effect of idebenone on respiratory function in nine ambulant FA patients. (31)P magnetic resonance spectroscopy demonstrated mitochondrial impairment in vivo in skeletal muscle of all FA patients, but no recovery with idebenone. No effects were seen in clinical scores. Echocardiography did not confirm a preliminary study reporting improvement of FA-associated cardiomyopathy with idebenone.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11406322     DOI: 10.1016/s0304-3940(01)01892-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

Review 1.  Friedreich ataxia-update on pathogenesis and possible therapies.

Authors:  Max Voncken; Panos Ioannou; Martin B Delatycki
Journal:  Neurogenetics       Date:  2003-12-19       Impact factor: 2.660

2.  Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia.

Authors:  Bart E Drinkard; Randall E Keyser; Scott M Paul; Ross Arena; Jonathan F Plehn; Jack A Yanovski; Nicholas A Di Prospero
Journal:  Arch Phys Med Rehabil       Date:  2010-07       Impact factor: 3.966

Review 3.  Ataxia rating scales--psychometric profiles, natural history and their application in clinical trials.

Authors:  Jonas Alex Morales Saute; Karina Carvalho Donis; Carmen Serrano-Munuera; David Genis; Luís Torres Ramirez; Pilar Mazzetti; Luis Velázquez Pérez; Pilar Latorre; Jorge Sequeiros; Antoni Matilla-Dueñas; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2012-06       Impact factor: 3.847

4.  Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome.

Authors:  Subha V Raman; Kavita Phatak; J Chad Hoyle; Michael L Pennell; Beth McCarthy; Tam Tran; Thomas W Prior; John W Olesik; Anthony Lutton; Chelsea Rankin; John T Kissel; Roula Al-Dahhak
Journal:  Eur Heart J       Date:  2010-12-14       Impact factor: 29.983

5.  Flavin adenine dinucleotide rescues the phenotype of frataxin deficiency.

Authors:  Pilar Gonzalez-Cabo; Sheila Ros; Francesc Palau
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

Review 6.  Clinical experience with high-dose idebenone in Friedreich ataxia.

Authors:  Jörg B Schulz; Nicholas A Di Prospero; Kenneth Fischbeck
Journal:  J Neurol       Date:  2009-03       Impact factor: 4.849

Review 7.  Idebenone: an emerging therapy for Friedreich ataxia.

Authors:  Thomas Meier; Gunnar Buyse
Journal:  J Neurol       Date:  2009-03       Impact factor: 4.849

Review 8.  Pharmacotherapy for Friedreich ataxia.

Authors:  Amy Y Tsou; Lisa S Friedman; Robert B Wilson; David R Lynch
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 9.  Diagnosis and treatment of Friedreich ataxia: a European perspective.

Authors:  Jörg B Schulz; Sylvia Boesch; Katrin Bürk; Alexandra Dürr; Paola Giunti; Caterina Mariotti; Francoise Pousset; Ludger Schöls; Pierre Vankan; Massimo Pandolfo
Journal:  Nat Rev Neurol       Date:  2009-04       Impact factor: 42.937

10.  Consensus paper: management of degenerative cerebellar disorders.

Authors:  W Ilg; A J Bastian; S Boesch; R G Burciu; P Celnik; J Claaßen; K Feil; R Kalla; I Miyai; W Nachbauer; L Schöls; M Strupp; M Synofzik; J Teufel; D Timmann
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.